858-449-1310 contact@somatek.com

The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, on Wednesday announced the results of an independent, scheduled data review of the Phase 3 Mosaico study of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified. The community had big hopes for this major study in the Americas and Europe after earlier trials in Africa and Asia had failed. What is next for HIV vaccines? Follow the discussion on LinkedIn.